ADD THIS DRUG TO MY LIST

Select the drug indication to add to your list

RELiZORB
Digestive and biliary disorders
Compare To Related Drugs
View/Edit/Compare Drugs In My List

Only 4 drugs may be compared at once

Drug Name:

RELiZORB Rx

Generic Name and Formulations:
Immobilized lipase (iLipase); per cartridge.

Company:
Alcresta Therapeutics, Inc.

Therapeutic Use:

Indications for RELiZORB:

To hydrolyze fats in enteral formula in patients ≥5yrs.

Adults and Children:

<5yrs: not established. ≥5yrs: use with enteral pump flow rates 24–120mL/hr. Use 1 cartridge for up to 500mL of enteral formula; if formula volume >500mL, may install a second cartridge for use immediately; max 2 cartridges per 24hr period. If formula volume <500mL per feeding, discard cartridge after use. For compatible enteral formulas, pumps, feed sets, and pump extension sets: see full labeling.

Warnings/Precautions:

For use with enteral feeding only. Do not connect to any IV line, set up, or system. Do not reuse. Not for use with gravity feed systems. Monitor patients with fibrosing colonopathy; may progress to stricture formation. Exocrine pancreatic insufficiency: not studied.

Interactions:

Avoid enteral formulas containing insoluble fiber. Do not administer or add other medications through the cartridge or to the enteral feed line (in between the pump and cartridge). Concomitant porcine pancreatic enzyme replacement therapy: not studied.

Pharmacological Class:

Digestive enzymes.

Generic Availability:

NO

How Supplied:

Single-use cartridge—1

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs